Oligonucleotides for htt-1a modulation
AssigneeUniversity of Massachusetts
InventorsAnastasia Khvorova, Julia Alterman, Socheata Ly, Faith Conroy, Daniel O'Reilly
Life of this patent
Estimating the term…
Abstract
This disclosure relates to novel HTT-1A targeting sequences. Novel HTT-1A targeting oligonucleotides for the treatment of neurodegenerative diseases are also provided.
Claims44
1-2. (canceled)
A double stranded RNA (dsRNA) molecule comprising a sense strand and an antisense strand, each strand with a 5′ end and a 3′ end, wherein:
- the sense strand is 15 nucleotides to 20 nucleotides in length and the antisense strand is 20 nucleotides to 25 nucleotides in length,
- the antisense strand comprises a sequence complementary to a huntingtin variant 1A (HTT-1A) nucleic acid sequence of SEQ ID NO:
- 544 or 545, and
- the antisense strand comprises at least 50% 2′-O-methyl nucleotide modifications.
(canceled)
(canceled)
8-9. (canceled)
11-12. (canceled)
14-16. (canceled)
18-21. (canceled)
24-27. (canceled)
(canceled)
31-33. (canceled)
36-37. (canceled)
39-44. (canceled)
(canceled)
49-53. (canceled)
55-56. (canceled)
58-62. (canceled)
65-68. (canceled)
71-79. (canceled)
A vector comprising a regulatory sequence operably linked to a nucleotide sequence that encodes a double stranded RNA (dsRNA) molecule comprising a sense strand and an antisense strand, each strand with a 5′ end and a 3′ end, wherein:
- the sense strand comprises 15 to 20 nucleotides in length and the antisense strand comprises 20 nucleotides to 25 nucleotides in length,
- the dsRNA molecule inhibits expression of a huntingtin variant 1A (HTT-1A) nucleic acid by at least 30%, and
- the antisense strand comprises a sequence comprising complementary to a HTT-1A nucleic acid sequence of SEQ ID NO:
- 544 or 545.
81-85. (canceled)
87-187. (canceled)
Dependencies are inferred from the claim text.